Antineoplastic Agents: Cytotoxic Agents: Alkylating Agents
IPARA1 “Paraplatin injection” 10 mg/ml; 45 ml/vial
適應症：卵巢癌。
Usual dose:
Non-small cell lung cancer, First-line in combination with paclitaxel and bevacizumab for advanced/metastatic non-squamous cell disease: paclitaxel 200 mg/m(2) IV, carboplatin (AUC of 6) IV, and bevacizumab 15 mg/kg IV, once q3w for 6 cycles, then bevacizumab alone until disease progression.
Ovarian cancer, Advanced (as initial treatment in combination with other approved chemotherapy agents): 300 mg/m(2) on day 1 q4w for 6 cycles or dose based on the Calvert formula, with a target area under the curve (AUC) of 4-6 mg/mL x min (total dose (mg)= target (AUC) x (GFR +25); area under the curve (AUC), glomerular filtration rate (GFR) in combination with cyclophosphamide 600 mg/m(2) IV on day 1 q4w for 6 cycles.
Ovarian cancer, Advanced (palliative treatment of recurrent disease, including patients previously treated with cisplatin): 360 mg/m(2) IV on day 1 q4w or dose based on the Calvert formula, with a target area under the curve (AUC) of 4-6 mg/mL x min (total dose (mg)= target (AUC) x (GFR +25); area under the curve (AUC), glomerular filtration rate (GFR).
Dose adjustment:
Hematologic: dosage adjustments in single-agent or combination therapy are based on the lowest post-treatment platelet and neutrophil counts; for platelets > 100,000/neutrophils > 2000, adjusted dose is 125% from prior course; for platelets < 50,000/neutrophils < 500, adjusted dose is 75% from prior course.
Renal impairment (for the initial course of therapy): CrCl 41-59 mL/min give 250 mg/m(2); CrCl 16-40 mL/min give 200 mg/m(2).
Geriatric: formula dosing based on estimates of glomerular filtration rate should be used to reduce the potential for toxicity and to provide appropriate predictions of carboplatin AUC levels.
Contraindication: severe myelosuppression/significant bleeding.
Precaution: aluminum reacts with carboplatin to form an inactive precipitate; extravasation; patients > 65 yrs or those previously treated with cisplatin are at increased risk of developing carboplatin-induced peripheral neuropathy; prior aminoglycoside therapy may potentiate carboplatin-induced renal toxicity; renal impairment; use proper procedures for handling and disposal of chemotherapy.
Adverse effect:
Common: nausea and vomiting.
Serious: electrolyte imbalance, myelosuppression, immune hypersensitivity reaction, peripheral neuropathy, visual disturbance.
健保使用規範：限
1.卵巢癌患者。
2.腎功能不佳(CCr < 60)或曾作單側或以上腎切除之惡性腫瘤患者使用。